NPI 1639444011: Open Payments
NPI 1639444011. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$962 in 27 payments from 12 companies in 2025. Trend: 2023 $3,479 · 2024 $1,700 · 2025 $962
Food & beverage: $962
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 5 | $224 |
| AstraZeneca Pharmaceuticals LP | 2 | $165 |
| Galderma Laboratories, L.P. | 3 | $151 |
| CSL Behring | 4 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $59 |
| GlaxoSmithKline, LLC. | 2 | $48 |
| Octapharma USA, Inc. | 2 | $48 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $45 |
| Optinose US, Inc. | 2 | $44 |
| Blueprint Medicines Corporation | 1 | $41 |
Products named: DUPIXENT, NEMLUVIO, FASENRA, Haegarda, CUVITRU, TRELEGY ELLIPTA, CUTAQUIG, NEFFY.
